Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

781 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.
Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, Stella P, Richel D, Szcylik C, Cascinu S, Frassineti GL, Ciuleanu T, Hurt K, Hynes S, Lin J, Lin AB, Von Hoff D, Calvo E. Laquente B, et al. Among authors: von hoff d. BMC Cancer. 2017 Feb 15;17(1):137. doi: 10.1186/s12885-017-3131-x. BMC Cancer. 2017. PMID: 28202004 Free PMC article. Clinical Trial.
Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base.
Albain KS, Crowley JJ, Hutchins L, Gandara D, O'Bryan RM, Von Hoff DD, Griffin B, Livingston RB. Albain KS, et al. Among authors: von hoff dd. Cancer. 1993 Aug 15;72(4):1184-91. doi: 10.1002/1097-0142(19930815)72:4<1184::aid-cncr2820720409>3.0.co;2-y. Cancer. 1993. PMID: 8393365 Clinical Trial.
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, Caprioni F, Van Cutsem E, Richel D, DeWitte M, Qi M, Robinson D Jr, Zhong B, De Boer C, Lu JD, Prabhakar U, Corringham R, Von Hoff D. Wiedenmann B, et al. Among authors: von hoff d. J Support Oncol. 2008 Jan;6(1):18-25. J Support Oncol. 2008. PMID: 18257397 Clinical Trial.
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD. Ramanathan RK, et al. Among authors: von hoff dd. Cancer Chemother Pharmacol. 2011 Mar;67(3):503-9. doi: 10.1007/s00280-010-1343-8. Epub 2010 May 12. Cancer Chemother Pharmacol. 2011. PMID: 20461382 Clinical Trial.
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R. Von Hoff DD, et al. J Clin Oncol. 2010 Nov 20;28(33):4877-83. doi: 10.1200/JCO.2009.26.5983. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921468
An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development.
Armstrong MD, Von Hoff D, Barber B, Marlow LA, von Roemeling C, Cooper SJ, Travis P, Campbell E, Paz-Fumagalli R, Copland JA, Colon-Otero G. Armstrong MD, et al. Among authors: von roemeling c, von hoff d. J Cancer. 2011 Mar 8;2:142-52. doi: 10.7150/jca.2.142. J Cancer. 2011. PMID: 21475719 Free PMC article.
781 results